Compounds > duloxetine
Page last updated: 2024-08-24

duloxetine and 2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine

duloxetine has been researched along with 2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (62.50)29.6817
2010's3 (37.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bish, G; Brown, AD; Fish, PV; Jonathan Fray, M; Stobie, A; Wakenhut, F; Whitlock, GA1
Bish, G; Fish, PV; Fray, MJ; Stobie, A; Wakenhut, F; Whitlock, GA1
Deur, C; Fish, PV; Gan, X; Greene, K; Hoople, D; Mackenny, M; Para, KS; Reeves, K; Ryckmans, T; Stiff, C; Stobie, A; Wakenhut, F; Whitlock, GA1
Alfinito, P; Bray, J; Cohn, ST; Deecher, DC; Fensome, A; Johnston, G; Koury, E; Mahaney, PE; Marella, MA; McComas, CC; Nogle, L; Trybulski, EJ; Vu, AT; Ye, F; Zhang, P1
Bray, JA; Cohn, ST; Deecher, DC; Dooley, R; Goljer, I; Johnston, GH; Leiter, J; Mahaney, PE; Moore, WJ; Terefenko, EA; Trybulski, EJ; Vu, AT; Zhang, P1
Bray, JA; Cohn, ST; Cosmi, SA; Deecher, DC; Harrison, JE; Johnston, GH; Kennedy, JD; Kim, CY; Koury, EJ; Leventhal, L; Mahaney, PE; Smith, VA; Trybulski, EJ; Vu, AT; Whiteside, GT; Zhang, P1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC1
Brennan, PE; Brown, AD; Bungay, PJ; Conlon, KM; Corbett, MS; de Oliveira, CA; DePianta, RP; Fish, PV; Heifetz, A; Ho, DK; Jessiman, AS; McMurray, G; Roberts, LR; Root, JA; Shanmugasundaram, V; Shapiro, MJ; Skerten, M; Storer, RI; Westbrook, D; Wheeler, S; Whitlock, GA; Wright, J1

Other Studies

8 other study(ies) available for duloxetine and 2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine

ArticleYear
N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.
    Bioorganic & medicinal chemistry letters, 2006, Aug-15, Volume: 16, Issue:16

    Topics: Amines; Chemistry, Pharmaceutical; Drug Design; Duloxetine Hydrochloride; Humans; Models, Chemical; Norepinephrine; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship; Thiophenes

2006
Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.
    Bioorganic & medicinal chemistry letters, 2006, Aug-15, Volume: 16, Issue:16

    Topics: Amines; Biological Transport; Cell Line; Chemistry, Pharmaceutical; Drug Design; Humans; Inhibitory Concentration 50; Models, Chemical; Piperazine; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship

2006
Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.
    Bioorganic & medicinal chemistry letters, 2008, Apr-15, Volume: 18, Issue:8

    Topics: Cells, Cultured; Drug Design; Humans; Liver; Molecular Structure; Morpholines; Norepinephrine; Selective Serotonin Reuptake Inhibitors; Serotonin; Stereoisomerism; Structure-Activity Relationship

2008
Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.
    Bioorganic & medicinal chemistry letters, 2008, Sep-15, Volume: 18, Issue:18

    Topics: Humans; Indoles; Molecular Structure; Neurotransmitter Uptake Inhibitors; Norepinephrine; Stereoisomerism; Structure-Activity Relationship

2008
3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.
    Bioorganic & medicinal chemistry letters, 2009, May-01, Volume: 19, Issue:9

    Topics: Adrenergic Uptake Inhibitors; Animals; Chemistry, Pharmaceutical; Dogs; Dopamine Plasma Membrane Transport Proteins; Drug Design; Humans; Inhibitory Concentration 50; Ligands; Models, Chemical; Norepinephrine; Propanolamines; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship

2009
1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.
    Journal of medicinal chemistry, 2010, Mar-11, Volume: 53, Issue:5

    Topics: Animals; Body Temperature Regulation; Female; Indoles; Magnetic Resonance Spectroscopy; Neurotransmitter Uptake Inhibitors; Norepinephrine Plasma Membrane Transport Proteins; Pain; Propanolamines; Rats; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship

2010
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
    Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24

    Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility

2010
Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT₂C) receptor agonists with exquisite functional selectivity over 5-HT₂A and 5-HT₂B receptors.
    Journal of medicinal chemistry, 2014, Jun-26, Volume: 57, Issue:12

    Topics: Animals; Azepines; Blood-Brain Barrier; Central Nervous System Agents; CHO Cells; Cricetulus; Dogs; Drug Design; Humans; Madin Darby Canine Kidney Cells; Permeability; Pyrimidines; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2B; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Agonists; Structure-Activity Relationship; Urinary Incontinence, Stress

2014